Extensive evidence supports the idea that abrogating PD-1 with CRISPR/Cas9 enhances the anti-tumor potency of both allogeneic and autologous CAR-T cells in hematological malignancies and solid tumors during preclinical and clinical evaluations [11, 29]. This evidence concerns the gene PDCD1 and neoplasm.